Format

Send to

Choose Destination
Clin Liver Dis. 2015 Nov;19(4):591-604, v. doi: 10.1016/j.cld.2015.06.001. Epub 2015 Aug 25.

Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era.

Author information

1
Department of Medicine, Center for Liver Diseases, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA. Electronic address: ateriaky@yahoo.com.
2
Department of Medicine, Center for Liver Diseases, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA.

Abstract

Hepatitis C is a major worldwide cause of liver morbidity and mortality. A substantial proportion of infected patients will develop chronic disease, which may progress over decades to cirrhosis. This can lead to decompensation and hepatocellular carcinoma. With the advent of the direct-acting antivirals, hepatitis C has become increasingly curable with limited adverse events and a shorter duration of therapy. This review discusses the evaluation process of the hepatitis C patient in the direct-acting antiviral era, including screening, clinical evaluation, drug-drug interactions, treatment urgency, and counseling.

KEYWORDS:

Assessment; Diagnosis; Direct-acting antivirals; Evaluation; Hepatitis C

PMID:
26466649
DOI:
10.1016/j.cld.2015.06.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center